JP2024542831A - Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法 - Google Patents

Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法 Download PDF

Info

Publication number
JP2024542831A
JP2024542831A JP2024533880A JP2024533880A JP2024542831A JP 2024542831 A JP2024542831 A JP 2024542831A JP 2024533880 A JP2024533880 A JP 2024533880A JP 2024533880 A JP2024533880 A JP 2024533880A JP 2024542831 A JP2024542831 A JP 2024542831A
Authority
JP
Japan
Prior art keywords
compound
pharma
acceptable salt
ceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533880A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023107894A5 (https=
JP2024542831A5 (https=
Inventor
マシュー・アンソニー・マウラー
マイケル・ガブリエル・オキグリー
リチャード・ザング
ジェイムズ・ホランド
マイ・ホープ・リ
サラ・シュウ－クアン・ジョー－ツァイ
Original Assignee
アイディアヤ バイオサイエンシーズ，インコーポレイティド
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイディアヤ バイオサイエンシーズ，インコーポレイティド, ファイザー・インク filed Critical アイディアヤ バイオサイエンシーズ，インコーポレイティド
Publication of JP2024542831A publication Critical patent/JP2024542831A/ja
Publication of JPWO2023107894A5 publication Critical patent/JPWO2023107894A5/ja
Publication of JP2024542831A5 publication Critical patent/JP2024542831A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024533880A 2021-12-06 2022-12-05 Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法 Pending JP2024542831A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163286345P 2021-12-06 2021-12-06
US63/286,345 2021-12-06
US202263317573P 2022-03-08 2022-03-08
US63/317,573 2022-03-08
US202263370056P 2022-08-01 2022-08-01
US63/370,056 2022-08-01
PCT/US2022/080928 WO2023107894A1 (en) 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Publications (3)

Publication Number Publication Date
JP2024542831A true JP2024542831A (ja) 2024-11-15
JPWO2023107894A5 JPWO2023107894A5 (https=) 2025-12-15
JP2024542831A5 JP2024542831A5 (https=) 2025-12-15

Family

ID=86731264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533880A Pending JP2024542831A (ja) 2021-12-06 2022-12-05 Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法

Country Status (8)

Country Link
US (1) US20240335440A1 (https=)
EP (1) EP4444303A4 (https=)
JP (1) JP2024542831A (https=)
AU (1) AU2022407330A1 (https=)
CA (1) CA3239676A1 (https=)
IL (1) IL313361A (https=)
MX (1) MX2024006948A (https=)
WO (1) WO2023107894A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174478A1 (en) * 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US11413284B2 (en) * 2017-09-12 2022-08-16 Novartis Ag Protein kinase C inhibitors for treatment of uveal melanoma
AU2020386903A1 (en) * 2019-11-18 2022-06-09 Ideaya Biosciences, Inc. Dosing regimens for a protein kinase C inhibitor
JP2023541011A (ja) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド 医薬組み合わせおよび腫瘍治療

Also Published As

Publication number Publication date
CA3239676A1 (en) 2023-06-15
EP4444303A4 (en) 2025-11-26
EP4444303A1 (en) 2024-10-16
AU2022407330A1 (en) 2024-07-04
US20240335440A1 (en) 2024-10-10
WO2023107894A1 (en) 2023-06-15
IL313361A (en) 2024-08-01
MX2024006948A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
EP3574904B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
AU2012321110B2 (en) Combination treatment
JP2016535756A (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
US20240207257A1 (en) Combination therapy comprising a pkc inhibitor and a mek inhibitor
JP7762796B2 (ja) Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
US11890292B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN115038447A (zh) 用于治疗癌症的组合疗法
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
KR20260005936A (ko) 간에만 전이된 포도막 흑색종의 치료 방법
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
TW202434219A (zh) 使用乏氧激活化合物治療對parp抑制劑耐藥的患者的藥物及其製藥用途
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251205